I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| natural killer cell | 21 studies | 24% ± 6% | |
| CD16-negative, CD56-bright natural killer cell, human | 10 studies | 28% ± 9% | |
| CD16-positive, CD56-dim natural killer cell, human | 9 studies | 25% ± 8% | |
| endothelial cell | 7 studies | 20% ± 4% | |
| adipocyte | 7 studies | 24% ± 5% | |
| mature NK T cell | 6 studies | 24% ± 10% | |
| ciliated cell | 5 studies | 27% ± 10% | |
| epithelial cell | 5 studies | 29% ± 11% | |
| B cell | 4 studies | 17% ± 1% | |
| endothelial cell of lymphatic vessel | 4 studies | 22% ± 4% | |
| CD8-positive, alpha-beta T cell | 3 studies | 18% ± 1% | |
| naive thymus-derived CD8-positive, alpha-beta T cell | 3 studies | 17% ± 1% | |
| gamma-delta T cell | 3 studies | 25% ± 2% | |
| lymphocyte | 3 studies | 24% ± 6% | |
| basal cell | 3 studies | 22% ± 2% | |
| innate lymphoid cell | 3 studies | 18% ± 2% | |
| hepatocyte | 3 studies | 31% ± 7% | |
| type I pneumocyte | 3 studies | 19% ± 1% | |
| T cell | 3 studies | 17% ± 2% |
